Pharmacological AD treatment today is focused on intervening in cognitive impairment and dysfunction of global activities through the use of cholinesterase inhibitors (donepezil, rivastigmine and galantamine), NMDA receptor modulators (memantine) and, most recently, immunotherapy (through the anti-Aβ monoclonal antibodies aducanumab and lecanemab). Here, BCHE is linked to Cognitive impairment.